HOME >> BIOLOGY >> NEWS
Amphetamine-related drugs ameliorate symptoms of Parkinson's

The debilitating effects of Parkinson's disease are well known: muscle rigidity, impaired movement, and the uncontrollable shaking that makes even the most mundane activity a challenge. The symptoms result from a progressive deterioration of neurons, found in the midbrain, that produce dopamine. With no cure on the horizon, the most common treatment involves administration of the dopamine precursor, L-DOPA, usually in pill form. Though symptoms subside at first, this treatment is rendered ineffective over time.

In a new study reported in the open-access journal PLoS Biology, Tatyana Sotnikova and colleagues from Duke University create a mouse model that recapitulates many of the symptoms of Parkinson's disease and use it to screen potential therapeutic drugs. By eliminating the dopamine transporter - the protein responsible for recycling the chemical into neurons - in mice, the authors reduced dopamine levels in the midbrain by 20-fold. In addition, chemically inhibiting dopamine production in these mice resulted in essentially unmeasurable levels of the neurotransmitter, since it could now neither be produced at normal levels nor be recycled.

The authors tested a number of drugs at various doses and found that in addition to L-DOPA-related treatments, drugs related to amphetamine were effective in ameliorating muscle rigidity, tremor, and impaired movement in these mice. Most effective was methylenedioxymethamphetamine HCl (MDMA), commonly known as ecstasy. It has been shown that amphetamines can trigger release of neurotransmitters such as dopamine, serotonin, and norepinephrine and cause sudden bursts in neurotransmission, leading to a feeling of alertness, increased muscular activity, and reduced fatigue. This study, however, shows that treating mice with MDMA does not increase dopamine levels; furthermore, treating the mice with drugs related to serotonin or norepinephrine did not ameliorate the disease's sympto
'"/>

Contact: Paul Ocampo
press@plos.org
415-624-1224
Public Library of Science
1-Aug-2005


Page: 1 2

Related biology news :

1. MIT model could predict cells response to drugs
2. New target for HIV/AIDS drugs and vaccine discovered
3. Modified mushrooms may yield human drugs
4. UGR researchers design an alternative to blood test to detect drugs in the body
5. Could fungal collection hold the key to new life-saving drugs?
6. Sensitivity to diverse range of chemotherapeutic drugs linked to common pathway
7. Scientists develop new drugs to fight colon and breast cancer more effectively
8. Anti-inflammatory drugs interact with HRT, and more
9. Generic biologic drugs unlikely to offer significant savings
10. Stem cells provide new tool for studying disease and identifying ALS drugs
11. Enhancing chemotherapys efficacy: New agent has synergistic effect with standard drugs

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Amphetamine related drugs ameliorate symptoms Parkinson

(Date:2/24/2015)... This report analyzes the worldwide markets for Face and ... and Voice Biometrics. The report provides separate comprehensive analytics for the ... Europe , Asia-Pacific , ... and Latin America . Annual estimates and forecasts ... historic analysis is provided for these markets. Market data and analytics ...
(Date:2/18/2015)... (NASDAQ: CPHD ) today announced that its executives ... to participate via webcast. , Cowen and Company Health ... 3, 2015 at 11.20 a.m. Eastern Time , Raymond ... Wednesday, March 4, 2015 at 10.25 a.m. Eastern Time ... these events, please visit Cepheid,s website at http://ir.cepheid.com ...
(Date:2/11/2015)... February 11, 2015 ... "Access Control Market by Product (Cards and Readers, Biometrics, ... Defense, Government, Industrial, Healthcare, Education) and By Geography - Global ... MarketsandMarkets, the Access Control Market is expected ... at a CAGR of 10.6% between 2014 ...
Breaking Biology News(10 mins):World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
(Date:3/4/2015)... Proove Biosciences , a commercial ... to announce the launch of their CME-accredited course ... of Pain”. , The continuing medical education program ... year. The focus of the program is to ... treatments, integrate appropriate pain management techniques, and incorporate ...
(Date:3/4/2015)... 2015 Vegalab announced the acquisition of Ecowin, ... year. As part of the acquisition, Ecowin rebranded itself ... his role as CEO for the company,s Korea operations. ... work alongside Koo and oversee developments at the new ... Koo founded Ecowin in 2008 to ...
(Date:3/4/2015)... 4, 2015 Lancée ... Paris en décembre 2011, l,étude collaborative ... », qui compare   l es microsphères ... sorafénib dans le carcinome hépatocellulaire avancé, a recruté ... foie avancé   ; les résultats sont attendus ...
(Date:3/3/2015)... , March 3, 2015  Halozyme Therapeutics, Inc. (NASDAQ: ... 2015 Global Healthcare Conference in Miami, FL ... PT. David A. Ramsay , Chief Financial Officer, will ... webcast through the "Investors" section of Halozyme,s corporate website at ... for 90 days following the event. To access the live ...
Breaking Biology Technology:Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2
Cached News: